AGLE-102 is a novel extracellular vesicle therapy being developed for the treatment of rare and immuno-dermatological disorders. WOBURN, Mass. , Aug.
14, 2024 /PRNewswire/ -- Aegle Therapeutics Corp., a clinical-stage biopharmaceutical company developing novel extracellular vesicle ("EV") therapies to address immune and inflammatory-based dermatological disorders, today announced that the first patient has been dosed in a Phase 1/2a clinical study evaluating AGLE-102TM for the treatment of the rare pediatric skin blistering disease DEB. AGLE-102 is an investigational product comprised of extracellular vesicles isolated from allogeneic stem cells using Aegle's proprietary methods.
AGLE-102 is a native composite of cell-derived nanoparticles that contain active biomolecules including proteins and nucleic acids with anti-inflammatory, immunomodulating, and tissue regenerating properties. "We are thrilled to announce the initiation of this Phase 1/2a clinical trial for DEB, a complex disease characterized by chronic blistering and excessive inflammation. Aegle is committed to advancing new therapies to address the continued unmet medical need of this patient population," said Shelley Hartman , Aegle's Chief Executive Officer.
Evangelos Badiavas, MD, PhD, Co-Founder and Chief Scientific Officer, said "AGLE-102 is designed to mimic the body's healing mechanism by delivering proteins, including collagen 7, and other important biomolecules such as nucleic acids that act by reducing i.